Cellectis to Participate in Multiple Investor Conferences in 2026

NEW YORK, Sept. 01, 2026 /CourierPR/ -- Cellectis, a clinical-stage biotechnology company leveraging gene-editing technology for life-saving therapies, will participate in a series of upcoming investor conferences, aiming to strengthen its presence in the biotech sector.

At the Wells Fargo 21st Annual Healthcare Conference in Boston, MA, on September 10, 2026, Cellectis will present from 12:50 to 1:20 p.m. Eastern Time. The company's management team will also be available for meetings with investors throughout the conference.

From September 15 to 16, 2026, Cellectis will attend the Baird 2026 Global Healthcare Conference in New York, followed by the Fall Focus: Barclays Biotech 1x1 Day in New York on October 6, 2026, and the Stifel 2026 Healthcare Conference in the same city from November 10 to 12, 2026. The company will also participate in the Jefferies Global Healthcare Conference in London from November 16 to 19, 2026.

Cellectis, known for its pioneering gene-editing platform, focuses on developing allogeneic cell and gene therapies for oncology. The company’s management team will be available for one-on-one meetings with attendees at these conferences to discuss the company's strategies and progress.